{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:24:03Z","timestamp":1792185843709,"version":"4.4.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jogc.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jogc.2019.10.039","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T18:27:54Z","timestamp":1578680874000},"page":"301-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6448-3166","authenticated-orcid":false,"given":"Robert L.","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0870-5481","authenticated-orcid":false,"given":"Christine","family":"Derzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Portman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogc.2019.10.039_bib0001","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/GME.0b013e318287342d","article-title":"Vaginal health in the United States. Results from the Vaginal Health: Insights, Views & Attitudes survey","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2019.10.039_bib0002","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13697137.2013.834493","article-title":"Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy","volume":"17","author":"Goldstein","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.jogc.2019.10.039_bib0003","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.maturitas.2013.12.005","article-title":"Long-term safety of ospemifene (52- week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women","volume":"77","author":"Simon","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.jogc.2019.10.039_bib0004","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2019.10.039_bib0005","first-page":"1939","article-title":"Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause\u2014a review","volume":"9","author":"Wurz","year":"2014","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jogc.2019.10.039_bib0006","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/1933719113497290","article-title":"Profile of ospemifene in the breast","volume":"20","author":"Berga","year":"2013","journal-title":"Reprod Sci"},{"key":"10.1016\/j.jogc.2019.10.039_bib0007","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/13697137.2019.1631789","article-title":"Effects of ospemifene on bone in postmenopausal women","volume":"22","author":"De Villiers","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.jogc.2019.10.039_bib0008","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2019.10.039_bib0009","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2019.10.039_bib0010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/GME.0000000000001292","article-title":"Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial","volume":"26","author":"Archer","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2019.10.039_bib0011","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/jwh.2017.6385","article-title":"Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials","volume":"27","author":"Simon","year":"2018","journal-title":"J Womens Health"},{"key":"10.1016\/j.jogc.2019.10.039_bib0012","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/13697137.2017.1284780","article-title":"Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy","volume":"20","author":"Bruyniks","year":"2017","journal-title":"Climacteric"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216319309818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216319309818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:36:30Z","timestamp":1761665790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216319309818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1701216319309818"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2019.10.039","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2019.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}